Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia [1]
10.1016/j.leukres.2004.11.017
Saved in:
Main Authors: | Chng, W.J., Tan, L.H.C. |
---|---|
Other Authors: | PATHOLOGY |
Format: | Others |
Published: |
2016
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/131711 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
by: Giuseppe Saglio, et al.
Published: (2018) -
Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)
by: Young Rok Do, et al.
Published: (2020) -
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
by: Hagop M. Kantarjian, et al.
Published: (2022) -
Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia
by: Jae Yong Kwak, et al.
Published: (2018) -
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
by: Philippe Rousselot, et al.
Published: (2018)